12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Deals

Vaxxas, Merck deal

Vaxxas granted Merck exclusive, worldwide rights to develop and commercialize an undisclosed Merck vaccine using Vaxxas' needle-free Nanopatch vaccine delivery technology. Merck also has an option to...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >